VIDEO: Balancing treatment, immunocompetence key in rheumatic disease

ByStacey L. Adams

In this Healio Video Perspective from the Congress of Clinical Rheumatology – East Annual Symposium, Cornelia Weyand, MD, PhD, professor of medicine and immunology at Mayo College of Medicine, professor of medicine at Stanford University School of Medicine and director of the Program in Immunity and Inflammation at Mayo Clinic, discusses the immune pathogenesis of vasculitis and how the pandemic has changed the understanding of the immune system.

“We have learned that patients that are on immunosuppressive therapy are more susceptible to infections, including COVID-19,” Weyand told Healio Rheumatology. “So, this has really encouraged us to become very vigilant in how we make a diagnosis of vasculitis and in choosing the right therapeutic approach so that we don’t overtreat our patients and that we can manage the disease while still keeping them immunocompetent and capable to fight against COVID and other viral infections.”

COVID variant — “We have learned that patients that are on immunosuppressive therapy are more susceptible to infections, including COVID-19,” **Cornelia Weyand, MD, PhD**, told *Healio Rheumatology*. *Source: Adobe Stock*

Published by:

Sources/Disclosures

Collapse

Source:

Weyand, C. Immune Checkpoints in Vasculitis; Presented at: Congress of Clinical Rheumatology-East annual symposium; August 12-15, 2021 (hybrid meeting).

Disclosures: Weyand reports no relevant financial disclosures.

Congress of Clinical Rheumatology Annual Meeting

Read more

VIDEO: Balancing treatment, immunocompetence key in rheumatic disease

Related Content